Marc Boutin, currently CEO of the National Health Council (NHC), brings 20 years of international leadership experience in health advocacy, policy and legislation. Throughout his professional career, he has focused on creating access to care through …
EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1Chronic rhinosinusitis with nasal polyps is a debilitating condition for man…
Kalwe, India: staying on site to ensure leprosy drug productionMultidrug therapy (MDT) was a major breakthrough in the fight against leprosy and remains the cornerstone of the global leprosy elimination strategy. The Sandoz Kalwe site, located north of…
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1 ASCLEPIOS I and II demonstrated significant reductions …
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously received FDA Regenerative Medicine Advanced Therapy (RMAT) des…
EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 Moderate-to-severe psoriasis affects more than 350,000 childr…
Novartis has entered into a research and development collaboration with Sangamo Therapeutics to explore potential gene regulation therapies for neurodevelopmental diseases. Proprietary technology platforms from both companies will be harnessed to facil…
At Novartis, our people are our most valuable resource. We want everyone to feel able to be their best selves at work and at home, and we are committed to supporting and enabling them to be inspired, curious and unbossed. The global pandemic has accele…
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (…
Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150 million would include major innovative technology development a…